Clinical Trial Update: To Assess the Relative Bioavailability (BA) of TRIUMEQ® and Dolutegravir and Lamivudine (DTG/3TC) Pediatric Dispersible Tablet Formulations in Healthy Volunteers [Phase 1]

View source ↗

Summary

A Phase 1 study assessing the relative bioavailability of DTG/3TC pediatric dispersible tablet formulations in healthy volunteers.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infections

Drugs mentioned

• DTG/3TC (dolutegravir/lamivudine)
• Triumeq (dolutegravir/abacavir/lamivudine)

Snippet

Sponsor: ViiV Healthcare | Conditions: HIV Infections | Phase 1 | Status: COMPLETED | Results posted: 2019-12-09